Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06479187 · ClinicalTrials.gov registry record · Phase 4
PSMAtrack-tracking Changes in PSMA-PET During Initial Therapy for Metastatic Hormone-sensitive Prostate Cancer
A Phase 4 study of Metastatic Prostate Cancer and Hormone Sensitive Prostate Cancer, sponsored by Brigham and Women's Hospital.
- Active
- Registry status
- Phase 4
- Development phase
- 20
- Enrollment target
- 2
- Study locations
NCT06479187: Active Phase 4 study of Metastatic Prostate Cancer and Hormone Sensitive Prostate Cancer, sponsored by Brigham and Women's Hospital.
NCT06479187 is a Phase 4 study of Metastatic Prostate Cancer and Hormone Sensitive Prostate Cancer that is active but no longer recruiting, run by Brigham and Women's Hospital. The registered enrollment target is 20 participants, below the 186-participant average among 41 other Metastatic Prostate Cancer trials with a reported enrollment target (89% lower). The trial reports 2 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06479187, a Phase 4 study of Metastatic Prostate Cancer and Hormone Sensitive Prostate Cancer, is active but no longer recruiting, sponsored by Brigham and Women's Hospital.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 4
- Development phase
- 20 participants
- Enrollment target
- 2
- Study locations
Study Summary
The goal of this clinical trial is to learn if serial PSMA-PET/CT scans can be used to monitor response to therapy in metastatic hormone sensitive prostate cancer and can be potentially used to optimize future treatment approaches. The main questions it aims to answer are: What is the proportion of men with residual PSMA-avid disease on PET/CT scans after 6 months of treatment for metastatic hormone sensitive prostate cancer? Do the findings on PSMA-PET/CT scans after 6 months of treatment for metastatic hormone sensitive prostate cancer correlate with other markers of disease status, like PSA? Participants will: Receive standard of care treatment for metastatic hormone sensitive prostate cancer Undergo a PSMA-PET/CT scan before starting treatment Undergo a PSMA-PET/CT scan after 6 months of treatment Have a chart review every 3 months for 1 year after the 6 month PSMA-PET/CT scan
Primary Outcome
metric use is percent of men with residual PSMA avid disease compared to all men undergoing the scan.
Conditions Studied
Interventions
- DRUG 18F-rhPSMA-7.3
- DEVICE PET/CT
Study Locations (2)
Massachusetts
- Dana Farber Cancer Institute - Boston
- Dana-Farber Cancer Institute - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2024-06-30 |
| Est. Completion | 2027-06-20 |
| Phase | Phase 4 |
What the registry record for NCT06479187 still lists
NCT06479187 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 20 participants, a relatively small participant target, below the 186-participant average among 41 other Metastatic Prostate Cancer trials with a reported enrollment target (89% lower).
The record links to 3 conditions, with Metastatic Prostate Cancer appearing as the primary indexed condition, and to 2 interventions - of which 18F-rhPSMA-7.3 is the first listed.
NCT06479187 reports a single indexed study location in Massachusetts.
Frequently Asked Questions
What is clinical trial NCT06479187 about?
NCT06479187 is a clinical study titled "PSMAtrack-tracking Changes in PSMA-PET During Initial Therapy for Metastatic Hormone-sensitive Prostate Cancer". The goal of this clinical trial is to learn if serial PSMA-PET/CT scans can be used to monitor response to therapy in metastatic hormone sensitive prostate cancer and can be potentially used to optimize future treatment approaches. The main questions it aims to answer are: What is the proportion o...
What is the current status of trial NCT06479187?
This trial is currently active not recruiting. It is a Phase 4 study. The enrollment target is 20 participants. The study started on 2024-06-30. Estimated completion is 2027-06-20.
What conditions does trial NCT06479187 study?
This clinical trial studies the following conditions: Metastatic Prostate Cancer, Hormone Sensitive Prostate Cancer, Metastatic Hormone-Sensitive Prostate Cancer (mHSPC).
What interventions are being tested in trial NCT06479187?
The interventions under investigation include: 18F-rhPSMA-7.3 (DRUG), PET/CT (DEVICE).
Who is sponsoring clinical trial NCT06479187?
This trial is sponsored by Brigham and Women's Hospital, which has 937 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06479187 being conducted?
This trial has 2 study locations across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Metastatic Prostate Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06479187's enrollment target sits among peer trials
20 38th of 41 higher than 4 of 41 other Metastatic Prostate Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Metastatic Prostate Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
18F-Fluciclovine PET/CT Impact on Predicting Clinical Outcome of 177Lu-PSMA-617 Therapy in Patients With Prostate Cancer
RECRUITING · Phase 4
-
Impact of Multimodal Telerehabilitation in Rural Patients With Metastatic Prostate Cancer
RECRUITING · NA
-
Study of AZD0754 in Participants With Metastatic Prostate Cancer
RECRUITING · Phase 1
-
Cabazitaxel +/- Carboplatin vs 177Lu-PSMA-617 in Metastatic Castrate-resistant Prostate Cancer
RECRUITING · Phase 2
-
Debunking the Frailty-sarcopenIa-ADT Axis in mEtastatic Prostate canceR With multiComponent Exercise: The FIERCE Trial
RECRUITING · NA
-
Study of Sipuleucel-T With or Without Continuing New Hormonal Agents in Metastatic Prostate Cancer
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00573339 · 20 participants
Cardiac Magnetic Resonance Imaging (MRI) Normal Reference Control Group Testing
- NCT00692939 · 20 participants · Phase 1
Autologous Stem Cell Transplantation for Crohn's Disease
- NCT00967785 · 20 participants · Phase 1
A Phase I Study of Mozobil in the Treatment of Patients With WHIMS
- NCT01406691 · 20 participants · Phase 4
Light Flashes to Treat Delayed Sleep Phase Disorder (DSPD)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI